Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG006A combination therapy in advanced hepatocellular carcinoma
CTR20260889Phase 2Active
- Sponsor
- Lepu Biopharma Co., Ltd.
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MRG006A in hepatocellular carcinoma (HCC), sponsored by Lepu Biopharma Co., Ltd.. Started Apr 2026; status: active.
02
Drugs
MRG006A
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20260889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260889.